Das Medizinportal
Menü

Das Medizinportal

Passwort vergessen?

Bitte geben Sie Ihren Ihre E-Mail-Adresse ein. Anweisungen zum Zurücksetzen des Passworts werden Ihnen umgehend per E-Mail übermittelt.

Literatur:

Aktuelle Diagnostik und Therapie des Dry Eye Disease (S. 10-16)
C. Jacobi
1. Jacobi C, Dietrich T, Cursiefen C et al. Das trockene Auge - Aktuelle Konzepte zu Klassifizierung, Diagnostik und Pathogenese. Ophhalmologe 2006;103:9-17.
2. Leitlinie Nr.11, „Trockenes Auge“ (Sicca-Syndrom) und Blepharitis © BVA und DOG (11/2015).
3. Craig JP, Nichols KK, Akpek E et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017;15(3):276-83.
4. Jacobi C, Wenkel H, Jacobi A et al. Hepatitis C and ocular surface disease. Am J Ophthalmol 2007;144:705-711.
5. Jacobi C, Bellios N, Jacobi A et al. Erhebungsbogen zur Anamnese und Diagnostik des trockenen Auges. Klin Monatsbl Augenheilkd 2011;228:226-233.
6. Cursiefen C, Seitz B, Kruse FE. Neurotrophe Keratopathie: Pathogenese, Klinik und Therapie. Ophthalmologe 2005;102:18-24.
7. Seitz B, Grüterich M, Cursiefen C et al. Konservative und chirurgische Therapie der neurotrophen Keratopathie. Ophthalmologe 2005;102:15-26.
8. Höh H. Lidkantenparallele konjunktivale Falten. In: Brewitt H, Zierhut M (Hrsg) Trockenes Auge 2001. Dr. Reinhard Kaden, Heidelberg.
9. Wolffsohn JS, Arita Reiko, Chalmers R et al. TFOS DEWS II Diagnostic Methodology Report. Ocul Surf 2017;15(3):544-579.
10. Sambursky R. Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. Clin Ophthalmol 2016;10:2337-2343.
11. Cursiefen C, Jacobi C, Dietrich T et al. Aktuelle Therapie des trockenen Auges. Ophthalmologe 2006;103:18-24.
12. Jacobi, C, Kruse FE, Cursiefen C, Prospective, randomized, controlled comparison of Systane UD eye drops versus Visine Intensiv 1% EDO eye drops for the treatment of moderate dry eye. J Ocul Pharmacol Ther 2012;28(6):598-603
13. Maskin SL. Intraductal Meibomian Gland Probing Relieves Symptoms of Obstructive Meibomian Gland Dysfunction. Cornea. 2010;29:1145-1152.
14. Blackie CA, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Curr Opin Ophthalmol 2015;26(4):306-313.
15. Gupta PK, Vora GK, Matossian C et al. Outcomes of intense pulse light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol 2016;51(4):249-253.
16. Geerling G, MacLennan S, Hatwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004;88(11):1467-1474.
17. Kaido M, Uchino M, Kojima T et al. Effects of Diquafosol Tetrasodium Administration on Visual Function in Short Break-Up Time Dry Eye. J Ocul Pharmacol 2013;29(6):595-603.
18. Keating GM. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs 2015;75(8):911-922.
19. Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther 2012; 29(7): 579-589.
20. Kinoshita S, Awamura S, Nakamichi N et al. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014;157(3):576-583.
21. Wakamatsu TH, Sant Anna AEBPP, Cristovam PC et al. Minor Salivary Gland Transplantation for Severe Dry Eyes. Cornea 2017;36 Suppl 1:S26-S33.
22. Gibson EJ, Stapleton F, Wolffsohn JS et al. Local synthesis of sex hormones: are there consequences for the ocular surface and dry eye? Br J Ophthalmol 2017;pii: bjophthalmol-2017-310610. doi: 10.1136/bjophthalmol-2017-310610. [Epub ahead of print] Review.
23. Messmer E. Pathophysiologie, Diagnostik und Therapie des trockenen Auges. Dtsch Ärztebl Int. 2015;112(5):71-81.

Biomechanik der Hornhaut als neuer Parameter in der Keratokonusdiagnostik?
(S. 18-22)
T. Eppig, C. Spira-Eppig, A. Langenbucher, B. Seitz
1. Eppig T, Spira-Eppig C, Seitz B, Goebels S, Szentmáry N, Langenbucher A. Topographie und Tomographie der Hornhaut zur Frühdiagnostik des Keratokonus. Zeitschrift für praktische Augenheilkunde 2016; 37:181–194
2. Rabinowitz YS. Videokeratographic indices to aid in screening for keratoconus. J Refract Surg 1995; 11:371–379
3. Wiegand W, Schroeder B, Hager A. Grundlagen der Applanationstonometrie. Klin Monbl Augenheilkd 2005; 222:552–557
4. Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg 2005; 31:156–162
5. Oculus Optikgeräte GmbH. Produktinformation Corvis(R) ST, 2017. Available at: www.oculus.de/de/produkte/tonometer/corvis-st/funktionen/. Accessed November 06, 2017
6. Vinciguerra R, Ambrósio R, Elsheikh A, Roberts CJ, Lopes B, Morenghi E, Azzolini C, Vinciguerra P. Detection of keratoconus with a new biomechanical index. J Refract Surg 2016; 32:803–810
7. Ambrósio R, Lopes BT, Faria-Correia F, Salomão MQ, Bühren J, Roberts CJ, Elsheikh A, Vinciguerra R, Vinciguerra P. Integration of Scheimpflug-Based Corneal Tomography and Biomechanical Assessments for Enhancing Ectasia Detection. J Refract Surg 2017; 33:434–443
8. Roberts CJ, Mahmoud AM, Bons JP, Hossain A, Elsheikh A, Vinciguerra R, Vinciguerra P, Ambrósio R. Introduction of two novel stiffness parameters and interpretation of air puff-induced biomechanical deformation parameters with a dynamic Scheimpflug analyzer. J Refract Surg 2017; 33:266–273
9. Müßig L, Zemova E, Pattmöller J, Seitz B, Eppig T, Szentmáry N, Langenbucher A. Gerätegestützte Diagnostikverfahren des Keratokonus im Vergleich. Klin Monbl Augenheilkd 2014; 231:1215–1223
10. Luz A, Lopes B, Hallahan KM, Valbon B, Ramos I, Faria-Correia F, Schor P, Dupps WJ, Ambrósio R. Enhanced combined tomography and biomechanics data for distinguishing forme fruste keratoconus. J Refract Surg 2016; 32:479–494
11. Labiris G, Giarmoukakis A, Gatzioufas Z, Sideroudi H, Kozobolis V, Seitz B. Diagnostic capacity of the keratoconus match index and keratoconus match probability in subclinical keratoconus. J Cataract Refract Surg 2014; 40:999–1005
12. Ali NQ, Patel DV, McGhee CNJ. Biomechanical responses of healthy and keratoconic corneas measured using a noncontact scheimpflug-based tonometer. Invest Ophthalmol Vis Sci 2014; 55:3651–3659
13. Vinciguerra R, Ambrósio R, Roberts CJ, Azzolini C, Vinciguerra P. Biomechanical characterization of subclinical keratoconus without topographic or tomographic abnormalities. J Refract Surg 2017; 33:399–407
14. Peña-García P, Peris-Martínez C, Abbouda A, Ruiz-Moreno JM. Detection of subclinical keratoconus through non-contact tonometry and the use of discriminant biomechanical functions. J Biomech 2016; 49:353–363

Therapeutische Ziele des Glaukom-Managements (S. 24-30)
A. Jünemann
1. European Glaucoma Society. Terminologie und Handlungsrichtlinien für die Glaukome. 3. Auflage.www.eugs.org. Editrice Dogma S.r.L. 2008.
2. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114: 1965-72
3. Broman AT, Quigley HA, West SK, Katz J, Munoz B, Bandeen-Roche K, Tielsch JM, Friedman DS, Crowston J, Taylor HR, Varma R, Leske MC, Bengtsson B, Heijl A, He M, Foster PJ. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008; 49: 66-76
4. Chauhan BC, Garway-Heath DF, Goñi FJ, Rossetti L, Bengtsson B, Viswanathan AC, Heijl A. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008;92 :569-73
5. Bengtsson B, Heijl A. A visual field index for calculation of glaucoma rate of progression. Am J Ophthalmol. 2008; 145: 343-53
6. Heijl A, Bengtsson B, Chauhan BC, Lieberman MF, Cunliffe I, Hyman L, Leske MC. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115: 1557-65
7. Martus P, Stroux A, Budde WM, Mardin CY, Korth M, Jonas JB. Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma. Am J Ophthalmol 2005; 139: 999-1009
8. Armaly MF. Interpretation of tonometry and ophthalmoscopy Invest Opthalmol 1969; 8: 105-124
9.AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of  intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429–40
10. Thorburn W. The accuracy of clinical applanation tonometry. Acta Ophthalmol 1978; 56: 1–55
11. Phelps CD, Phelps GK. Measurement of intraocular pressure: a study of its reproducibility. Graefe’s Arch Clin Exp Ophthalmol 1976; 198: 39–43
12. Rosentreter A, Neuburger M, Jordan JF, Schild AM, Dietlein TS. Einflußgrößen auf die Applanationstonometrie – ein praxisorientierter Überblick. Klin Monatsbl Augenheilkd 2011; 228: 109-113
13. Doughty MJ, Jonuscheit S. The orbscan acoustic (correction) factor for central corneal thickness measures of normal human corneas. Eye Contact Lens 2010; 36: 106-15
14. Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group, Gordon MO, Torri V, Miglior S, Beiser JA, Floriani I, Miller JP, Gao F, Adamsons I, Poli D, D'Agostino RB, Kass MA. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007; 114: 10-9
15. European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 2007; 114: 3-9
16. Velten IM, Bergua A, Horn FK, Jünemann A, Korth M. Central corneal thickness in normal eyes, patients with ocular hypertension, normal-pressure and open-angle glaucomas--a clinical study]. Klin Monbl Augenheilkd 2000; 217: 219-24
17. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120: 1268-79
18. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-53
19. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group. Am J Ophthalmol 1995; 120: 10-22
20. Gherghel D, Orgül S, Gugleta K, Gekkieva M, Flammer J. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000; 130: 597-605
21. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–13
22. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268–79
23. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505
24. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126: 487-97
25. Jonas JB, Budde WM. Diagnosis and pathogenesis of glaucomatous optic neuropathy: morphological aspects. Prog Retin Eye Res 2000; 19: 1-40
26. Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Srra LM, Renard JP, Stefánsson E. The impactof ocular blood flow on glaucoma. Prog Retin Eye Res 2002; 21: 359-393
27. Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J. Optic nerve and neuroprotection strategies. Eye 2004; 18: 1075-1084
28. Quigley HA, Jampel HD. How are glaucoma patients identified? J Glaucoma 2003; 12 : 451-455
29. Olthoff CM, Schouten JS, van de Borne BW, Webers WA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. An evidence-based review. Ophthalmology 2005; 112: 953-961
30. Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics 2007; 25: 287-308

Therapie der akuten und chronischen Chorioretinopathia Centralis Serosa mit dem Nanolaser (S. 34-35)
H. Kaymak, R. Fulga, K. Klabe
1. Therapieoption bei chronischer Chorioretinopathia centralis serosa: Photodynamische Therapie kombiniert mit Bevacizumab – eine Fallserie / Therapy options for chronic central serous chorioretinopathy: Photodynamic therapy combined with bevacizumab – a case series. Maier M, Valet V, Feucht N, Lohmann C P, Der Ophthalmologe, Volume 108, Number 11, 1027-1031, DOI: 10.1007/s00347-011-2419-5